Drug-drug interactions. An update;Interacciones medicamentosas. Nuevos aspectos

Medicina Clinica

Volumn 127, Issue 7, 2006, Pages 269-275

  Morales Olivas, Francisco J ^a,b   Estañ, Luis ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Adverse drug reactions; Cytochrome P450; Drug drug interactions; Drug food interactions; Therapeutic failure

Indexed keywords

AMIODARONE; AMITRIPTYLINE; ANTIFUNGAL AGENT; BROMOCRIPTINE; CIMETIDINE; CYCLOSPORIN; CYTOCHROME P450; DESIPRAMINE; DIGOXIN; DILTIAZEM; ERYTHROMYCIN; FELODIPINE; GLYCOPROTEIN P; IMIPRAMINE; LOSARTAN; MACROLIDE; METOPROLOL; MEVINOLIN; MIDAZOLAM; NEFAZODONE; NICARDIPINE; OMEPRAZOLE; PROPAFENONE; PROPRANOLOL DERIVATIVE; SAQUINAVIR; TACROLIMUS; TRIAZOLAM; UNINDEXED DRUG; VENLAFAXINE; VERAPAMIL;

CLINICAL PRACTICE; DRUG EFFECT; DRUG METABOLISM; FOOD DRUG INTERACTION; GRAPEFRUIT; INCIDENCE; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW;

EID: 33748429609     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13091269     Document Type: Review

References (57)

1. Nies AS. Principles of therapeutics. En: Hardman JG, Limbird LE, editors. Goodman & Gilman's. The pharmacological basis of therapeutics. New York: McGraw-Hill; 2001. p. 45-66.
2. European Agency for the evaluation of medicinal products. Note for guidance on the investigation of drug interactions. London, 17-12-1997. CPMP/EWP/560/95.
3. Weideman RA, McKinney WP, Bernstein IH. Predictors of potential drug interactions. Hosp Pharm. 1998;33:835-40.
4. Morales-Olivas FJ, Estan L. Interacciones farmacológicas de los fármacos antihipertensivos. Med Clin (Barc). 2005;124:782-9.
5. Janchawee B, Wongpoowarak W, Owatranporn T, Chongsuvivatwong V. Pharmacoepidemiologic study of potencial drug interaction in outpatients of a university hospital in Thailand. J Clin Pharm Ther. 2005; 30:13-20.
6. Martín MT, Codina C, Tuset M, Carné X, Nogué S, Ribas J. Problemas relacionados con la medicación como causa del ingreso hospitalario. Med Clin (Barc). 2002;118:205-10.
7. Egger SS, Drewe J, Schlienger RG. Potential drug-drug interactions in the medication of medical patients at hospital discharge. Eur J Clin Pharmacol. 2003;58:773-8.
8. Kelly WN. Can the frequency and risks of fatal adverse drug events be determined? Pharmacotherapy. 2001;21:521-7.
9. Morales-Olivas FJ, Arístegui I, Estañ L, Rodicio JL, Moreno A, Gil V, et al. The KARTAN Study: a postmarketing assessment of irbesartan in patients with hypertension. Clin Ther. 2004;26:232-44.
10. Encuesta Nacional de Salud 2003. Ministerio de Sanidad y Consumo [consultado 17/10/20051. Disponible en: http://www.msc.es/sns/ sistemasInformacion/encuesta/encuesta2003/doc/Utilizacion_de_Servicios_S anitarios_Nacional.XLS
11. López-Torres Hidalgo J, Cerda Díaz R, Fernández Olano C, Requena Gallego M, Fernández Casalderrey C, Otero Puime A. Factores asociados al consumo de medicación crónica en personas ancianas. Med Clin (Barc). 1997;108:572-6.
12. Gri E, Vázquez F, Barroso A, Cantero M, Monjo M, Juncosa S, et al. Consumo de medicamentos y remedios naturales en la población anciana de un área rural. Aten Primaria. 1999;23:455-60.
13. a ed. Barcelona: Masson; 2003; p. 175-89.
14. a ed. Madrid: Panamericana; 2005. p. 1077-86.
15. Verschraagen M, Koks CHW, Schellens JHM, Beijnen JH. P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. Pharmacol Res. 1999;40:301-6.
16. Schenkman JB. Cytochromes P-450: historical overview. En: Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M, editors. Metabolic drug interactions. Philadelphia: Lippincott Williams and Wilkins; 2000. p. 51-60.
17. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy. 1998;18:84-112.
18. Martin J, Krum H. Cytochrome P450 drug interactions within the HMG-CoA reductase inhibitor class: are they clinically relevant? Drug Saf. 2003;26:13-21.
19. Malhotra HS, Goa KL. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. Drugs. 2001;61:1835-81.
20. Ingelman-Sundberg M. Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn-Schmiedeberg's Arch Pharmacol. 2004;369:89-104.
21. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. TIPS. 2004;25: 193-200.
22. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA. 2001;286:2270-9.
23. Zhang QY, Dunbar D, Ostrowska A, Zeisloft S, Yang J, Kaminsky LS. Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos. 1999;27:804-9.
24. Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Ann Rev Pharmacol Toxicol. 1999;39:1-17.
25. Furh U. Drug interactions with grapefruit juice: extent, probable mechanism and clinical relevance. Drug Saf. 1998;18:251-72.
26. Markowitz JS, Donovan JL, DeVane CL, Taylor RM, Ruan Y, Wang J, et al. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA. 2003;290:1500-4.
27. a ed. Madrid: Panamericana; 2005. p. 1125-45.
28. Hartshorn EA, Tatro DS. Principles of drug interactions. En: Tatro DS, editor. Drug interaction facts. St. Louis: Wolters Kluwer Health Inc.; 2005; p. XVII-XXXI.
29. Kiang TK, Ensom MH, Chang TK. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther. 2005;106:97-132.
30. Johnstone RW, Ruefi AA, Smyth MJ. Multiple physiological functions for multidrug transporter P-glycoprotein? TIBS. 2000;25:1-6.
31. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999;274:37161-8.
32. Fromm MF. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther. 2000;38:69-74.
33. Matheny CJ, Lamb MW, Brouwer KR, Pollack GM. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy. 2001;21:778-96.
34. Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001;276:14581-7.
35. Von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M, Kivisto KT. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther. 2004;75:172-83.
36. Lill J, Bauer LA, Horn JR, Hansten PD. Cyclosporine-drug interactions and the influence of patient age. Am J Health Syst Pharm. 2000;57:1579-84.
37. Wang E, Casciano CN, Clement RP, Johnson WW. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm Res. 2001;18:800-6.
38. Shitara Y, Sato H, Sugiyama Y. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Ann Rev Pharmacol Toxicol. 2005;45:689-723.
39. Brown GR. Cephalosporin-probenecid drug interactions. Clin Pharmacokinet. 1993;24:289-300.
40. Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the OATP2 (OATP1B1: SLC21A6)-mediated hepatic uptake and CYP2C8 mediated metabolism of cerivastatin-analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther. 2004;311:228-36.
41. De Bias Matas B, Laredo Velasco LM, Vargas Castrillón E. Interacciones de los fármacos más consumidos. Inf Ter Sist Nac Salud. 2004;28:1-11.
42. Bailey DG, Arnold JM, Spence JD. Grapefruit juice-drug interactions. Br J Clin Pharmacol. 1998;46:101-10.
43. Goosen TC, Cillie D, Bailey DG, Yu C, He K, Hollenberg PF, et al. Bergamottin contribution to the grapefruit juice-felodipine interaction and disposition in humans. Clin Pharmacol Ther. 2004;76:607-17.
44. Saito M, Hirata-Koizumi M, Matsumoto M, Urano T, Hasegawa R. Undesirable effects of citrus juice on the pharmacokinetics of drugs: focus on recent studies. Drug Saf. 2005;28:677-94.
45. Suvarna R, Pirmohamed M, Henderson L. Possible interaction between warfarin and cranberry juice. BMJ. 2003;327:1454.
46. Izzo AA. Drug interactions with St. John's wort (Hypericum perforatum): a review of the clinical evidence. Int J Clin Pharmacol Ther. 2004;42:139-48.
47. Estañ L, Morales-Olivas FJ. Interacciones de las estatinas. Latido. 2003; 9:352-5.
48. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005;352:2211-21.
49. Tirkkonen T, Laine K. Drug interactions with the potential to prevent pro-drug activation as a common source of irrational prescribing in hospital inpatients. Clin Pharmacol Ther. 2004;76:639-47.
50. Morales-Olivas FJ, Estañ L. ¿Interacciones o asociaciones potencialmente peligrosas? Aten Primaria. 2003;32:393-4.
51. Malone OC, Abarca J, Hansten PD, Grizzle AJ, Armstrong EP, Van Bergen RC, et al. Identification of serious drug-drug interactions: results of the partnership to prevent drug-drug interactions. Am J Geriatr Pharmacother. 2005;3:65-76.
52. Bergk V, Haefeli WE, Gasse C, Brenner H, Martin-Facklam M. Information deficits in the summary of product characteristics preclude an optimal management of drug interactions: a comparison with evidence from the literature. Eur J Clin Pharmacol. 2005;61:327-35.
53. Saito M, Hirata-Koizumi M, Miyake S, Hasegawa R. Comparison of information on the pharmacokinetic interactions of Ca antagonists in the package inserts from three countries (Japan, USA and UK). Eur J Clin Pharmacol. 2005;61:531-6.
54. San Miguel MT, Martínez JA, Vargas E. Food-drug interactions in the summary of product characteristics of proprietary medicinal products. Eur J Clin Pharmacol. 2005;61:77-83.
55. Martínez-Abad M, Delgado Gomis F, Ferrer JM, Morales-Olivas FJ. Ranitidine-induced confusion with concomitant morphine. Drug Intell Clin Pharm. 1988;22:914-5.
56. Pérez Plasencia A, Soy D, Nicolás JM. Interacción farmacocinética entre el ácido valproico y el meropenem. Med Clin (Barc). 2004;123:38.
57. Vergara-López S, García-García JA, Merchante N, Mira JA. Intoxicación digitálica secundaria a una alteración del metabolismo intestinal de la digoxina en una paciente tratada con claritromicina. Med Clin (Barc). 2004;123:639.